D46 类别:需要更具体的编码 Myelodysplastic syndromes
ICD-10-CM D46 identifies “Myelodysplastic syndromes” as a category requiring further specificity in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
章节 2: Neoplasms
编码说明
Excludes 21
drug-induced aplastic anemia (D61.1)
Use additional code1
code for adverse effect, if applicable, to identify drug (T36-T50 with fifth or sixth character 5)
上级编码说明
章节 2 · Neoplasms (C00-D49)
Note8
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
D37-D48 · Neoplasms of uncertain behavior, polycythemia vera and myelodysplastic syndromes (D37-D48)
Excludes 11
neoplasms of unspecified behavior (D49.-)
Note1
Categories D37-D44, and D48 classify by site neoplasms of uncertain behavior, i.e., histologic confirmation whether the neoplasm is malignant or benign cannot be made.
更具体的编码
D46.0Refractory anemia without ring sideroblasts, so stated可计费的具体编码D46.1Refractory anemia with ring sideroblasts可计费的具体编码D46.2Refractory anemia with excess of blasts [RAEB]类别:需要更具体的编码D46.4Refractory anemia, unspecified可计费的具体编码D46.9Myelodysplastic syndrome, unspecified可计费的具体编码D46.ARefractory cytopenia with multilineage dysplasia可计费的具体编码D46.BRefractory cytopenia with multilineage dysplasia and ring sideroblasts可计费的具体编码D46.CMyelodysplastic syndrome with isolated del(5q) chromosomal abnormality可计费的具体编码D46.ZOther myelodysplastic syndromes可计费的具体编码官方索引引用
其他编码的引用 (5)
Excludes 1 · myelodysplastic syndromes (D46.-)
Code also · myelodysplastic syndrome (D46.-)
Excludes 2 · pancytopenia (due to) (with) myelodysplastic syndromes (D46.-)
Excludes 1 · refractory anemia (D46.-)
Use additional code · code, if applicable, for associated therapy-related myelodysplastic syndrome (D46.-)
历史
编码历史
自首次收录以来无变更记录
生效日期
- 首次收录
Myelodysplastic syndromes
类别 — 请选择更具体的编码
CDC/NCHS · FY2016所有版本 (19)
| 所有版本 | 生效日期 | 编码历史 |
|---|---|---|
| FY2016 | 2015-10-01 | 首次收录 |
| FY2017 | 2016-10-01 | 分类表无变更 |
| FY2018 | 2017-10-01 | 分类表无变更 |
| FY2019 | 2018-10-01 | 分类表无变更 |
| FY2020 | 2019-10-01 | 分类表无变更 |
| FY2020 · April | 2020-04-01 | 分类表无变更 |
| FY2021 | 2020-10-01 | 分类表无变更 |
| FY2021 · 01-01 | 2021-01-01 | 分类表无变更 |
| FY2022 | 2021-10-01 | 分类表无变更 |
| FY2022 · 04-01 | 2022-04-01 | 分类表无变更 |
| FY2023 | 2022-10-01 | 分类表无变更 |
| FY2023 · 04-01 | 2023-04-01 | 分类表无变更 |
| FY2024 | 2023-10-01 | 分类表无变更 |
| FY2024 · 04-01 | 2024-04-01 | 分类表无变更 |
| FY2025 | 2024-10-01 | 分类表无变更 |
| FY2025 · 04-01 | 2025-04-01 | 分类表无变更 |
| FY2026 | 2025-10-01 | 分类表无变更 |
| FY2026 · April | 2026-04-01 | 分类表无变更 |
| FY2027 | 2026-10-01 | 分类表无变更 |
浏览此类别中更具体的编码。 参考核验不能确定临床适用性,也不保证报销。